Return to: Top news
Updated: July 8, 2022 at 3:40 p.m.
The Racing Medication & Testing Consortium (RMTC) has announced that it will fund the research proposal “Detection of Bisphosphonates Using Metabolomics”, submitted by Dr. Bethany Keen of the Equine Research and Testing Laboratory of the University of Pennsylvania. To date, Dr. Keen’s research has been conducted in Australia and has focused on equine anti-doping, analytical chemistry and statistics.
Metabolomics is an emerging field in doping control and represents a new testing approach that identifies cellular effects unique to a class of drugs rather than identifying the specific molecule responsible for those effects.
“The CCDR is proud to support the professional development of young scientists who are the future of our drug testing and research programs,” said Alex Waldrop, CCDR Board Chair. “It is particularly gratifying to be able to fund Dr. Keen, as she will be under the supervision and tutelage of Dr. Mary Robinson, whose own postgraduate training program was funded by CCDR more than 10 years ago.
“The recruitment and retention of motivated, highly qualified personnel and the support of competitive research programs are essential to anti-doping, medication control and racing safety programs,” said Dr. Mary Scollay, Executive Director and Chief exploitation. “The racing industry has a responsibility to seek out qualified people, support their advanced training, provide incentives for relevant research programs and foster productivity in research laboratories.”
Not a subscriber ? Click here to sign up for the Daily PDF or Alerts.
This story was published in Top news and tagged Alex Waldrop, Detection of bisphosphonates using metabolomics, Dr. Mary Scollay, equine anti-doping, Running Drugs Testing Consortium, CRM.
#Drugs #Running #Tests #Consortium #Fund #Postdoctoral #Fellowship